WO2004043336A3 - Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases - Google Patents

Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases Download PDF

Info

Publication number
WO2004043336A3
WO2004043336A3 PCT/US2003/011325 US0311325W WO2004043336A3 WO 2004043336 A3 WO2004043336 A3 WO 2004043336A3 US 0311325 W US0311325 W US 0311325W WO 2004043336 A3 WO2004043336 A3 WO 2004043336A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cytokine inhibitory
selective cytokine
compositions
management
Prior art date
Application number
PCT/US2003/011325
Other languages
French (fr)
Other versions
WO2004043336A2 (en
Inventor
Jerome B Zeldis
Original Assignee
Celgene Corp
Jerome B Zeldis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Jerome B Zeldis filed Critical Celgene Corp
Priority to BR0316002-5A priority Critical patent/BR0316002A/en
Priority to US10/534,324 priority patent/US20060165649A1/en
Priority to JP2004551394A priority patent/JP2006507324A/en
Priority to CA002505003A priority patent/CA2505003A1/en
Priority to MXPA05004777A priority patent/MXPA05004777A/en
Priority to EP03811178A priority patent/EP1569903A4/en
Priority to AU2003226361A priority patent/AU2003226361B2/en
Priority to NZ540384A priority patent/NZ540384A/en
Publication of WO2004043336A2 publication Critical patent/WO2004043336A2/en
Publication of WO2004043336A3 publication Critical patent/WO2004043336A3/en
Priority to IL168444A priority patent/IL168444A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)

Abstract

Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agent is capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of MPD. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
PCT/US2003/011325 2002-11-06 2003-04-13 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases WO2004043336A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BR0316002-5A BR0316002A (en) 2002-11-06 2003-04-13 Methods of treating or preventing and controlling a myeloproliferative disease, reducing or preventing an adverse effect associated with the administration of a second active agent in a patient suffering from a myeloproliferative disease, and enhancing the therapeutic efficacy of a myeloproliferative disease treatment, composition. pharmaceutical and kit
US10/534,324 US20060165649A1 (en) 2002-11-06 2003-04-13 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
JP2004551394A JP2006507324A (en) 2002-11-06 2003-04-13 Compositions comprising selective cytokine inhibitors for the treatment and management of myeloproliferative diseases and methods of use thereof
CA002505003A CA2505003A1 (en) 2002-11-06 2003-04-13 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
MXPA05004777A MXPA05004777A (en) 2002-11-06 2003-04-13 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases.
EP03811178A EP1569903A4 (en) 2002-11-06 2003-04-13 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
AU2003226361A AU2003226361B2 (en) 2002-11-06 2003-04-13 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
NZ540384A NZ540384A (en) 2002-11-06 2003-04-13 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
IL168444A IL168444A (en) 2002-11-06 2005-05-05 Selective cytokine inhibitory drugs for use in treating, preventing or managing a myeloproliferative diseases, a pharmaceutical composition and a kit comprising same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42473102P 2002-11-06 2002-11-06
US60/424,731 2002-11-06

Publications (2)

Publication Number Publication Date
WO2004043336A2 WO2004043336A2 (en) 2004-05-27
WO2004043336A3 true WO2004043336A3 (en) 2004-07-29

Family

ID=32312867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/011325 WO2004043336A2 (en) 2002-11-06 2003-04-13 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases

Country Status (13)

Country Link
US (1) US20060165649A1 (en)
EP (1) EP1569903A4 (en)
JP (1) JP2006507324A (en)
KR (1) KR20050072790A (en)
CN (1) CN1720226A (en)
AU (1) AU2003226361B2 (en)
BR (1) BR0316002A (en)
CA (1) CA2505003A1 (en)
IL (1) IL168444A (en)
MX (1) MXPA05004777A (en)
NZ (1) NZ540384A (en)
WO (1) WO2004043336A2 (en)
ZA (1) ZA200503653B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
WO2005112917A1 (en) * 2004-05-05 2005-12-01 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
US7700608B2 (en) 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
PT3300601T (en) * 2007-02-16 2022-04-21 Celator Pharmaceuticals Inc Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
EP2114415A4 (en) 2007-02-23 2012-10-17 Univ Louisville Res Found Methods and compounds for the targeted delivery of agents to bone for interaction therewith
WO2017030892A1 (en) 2015-08-14 2017-02-23 Reaction Biology Corp. Histone deacetylase inhibitors and methods for use thereof
CN112402613A (en) * 2019-08-23 2021-02-26 中国科学院上海药物研究所 Use of PDE3 inhibitors in combination with cytokines for the treatment of tumors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) * 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
IT1270594B (en) * 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5801195A (en) * 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
IT1274549B (en) * 1995-05-23 1997-07-17 Indena Spa USE OF FLAVANOLIGNANI FOR THE PREPARATION OF MEDICATIONS FOR ANTI-PROLIFERATIVE ACTIVITY IN CANCER OF THE UTERUS, OVARIAN AND BREAST
US5643915A (en) * 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5658940A (en) * 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
KR100539031B1 (en) * 1996-08-12 2005-12-27 셀진 코포레이션 Novel immunotherapeutic agents and their use in the reduction of cytokine levels
TR200000221T2 (en) * 1997-07-31 2000-09-21 Celgene Corporation Modified alkanohydroxamic acids and TNF alpha reduction method.
US6015803A (en) * 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
EP1079231A4 (en) * 1998-05-15 2003-07-23 Sekisui Chemical Co Ltd Immunoassay reagents and immunoassay method
US6225348B1 (en) * 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) * 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US6326388B1 (en) * 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
BR0110877A (en) * 2000-05-15 2003-03-11 Celgene Corp Methods of treating primary cancer, increasing the dosage of a topoisomerase inhibitor, reducing or preventing an adverse effect associated with chemotherapy and radiation therapy, increasing the therapeutic efficacy of a topoisomerase inhibitor, and protecting a cancer patient from adverse effects associated with administration of an anti-cancer drug, pharmaceutical composition, dosage form, and kit for use in cancer treatment
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
SE0200667D0 (en) * 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
NZ535349A (en) * 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
AU2003222034A1 (en) * 2002-03-20 2003-10-08 Celgene Corporation (-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
KR101059041B1 (en) * 2002-05-17 2011-08-24 셀진 코포레이션 Methods and compositions for using selective cytokine inhibitory drugs for the treatment and treatment of cancer and other diseases
US20040167199A1 (en) * 2002-11-18 2004-08-26 Celgene Corporation Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
KR20050090435A (en) * 2002-12-30 2005-09-13 셀진 코포레이션 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses
WO2004078144A2 (en) * 2003-03-05 2004-09-16 Celgene Corporation Diphenylethylene compounds and uses thereof
CA2518584A1 (en) * 2003-03-12 2004-09-23 Celgene Corporation 7-amino- isoindolyl compounds and their pharmaceutical uses
MXPA05009535A (en) * 2003-03-12 2005-11-16 Celgene Corp N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses.
US7405237B2 (en) * 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CANEPA L. ET AL: "Antitumor activity of thalidomide in idopathic myelofibrosis", HAEMATOLOGICA, vol. 86, no. 11, November 2001 (2001-11-01), pages 12 - 14, XP008103511 *
HAO ET AL: "Expression of Interferon Consensus Sequence Binding Protein (ICSBP) Is downregulated in Bcr-Abl-Induced Murine Chronic Myelogenous Leukemia-Like Disease, and Forced Coexpression of ICSBP Inhibits Bcr-Abl-Induced Myeloproliferative Disorder", MOLEC. CELL. BIOL., vol. 20, no. 4, February 2000 (2000-02-01), pages 1149 - 1161, XP002978089 *
LUNDBERG ET AL: "Bone Marrow in Polycythemia Vera, Chronic Myelocytic Leukemia, and MyelofibrosisHas an Increased Vascularity", AM. J. PATHOL., vol. 157, no. 1, July 2000 (2000-07-01), pages 15 - 19, XP002978092 *
PRUNERI ET AL: "Angiogenesis in myelodysplastic syndromes", BR. J. CANCER, vol. 81, no. 8, 1999, pages 1398 - 1401, XP002978091 *
SCHANDENE ET AL: "Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia", BLOOD, vol. 96, no. 13, 15 December 2000 (2000-12-15), pages 4285 - 4292, XP002978088 *
SILVER R.T.: "Interferon-Alpha 2b: A New Treatment for Polycythemia Vera", ANNALS OF INTERNAL MEDICINE, vol. 119, no. 11, 1 December 1993 (1993-12-01), pages 1091 - 1092, XP002978090 *
VACCA A. ET AL: "Angiogenesis in hematologic malignancies", HAEMATOLOGICA, vol. 86, no. 11, November 2001 (2001-11-01), pages 1 - 5, XP008103510 *

Also Published As

Publication number Publication date
AU2003226361B2 (en) 2009-01-22
BR0316002A (en) 2005-09-13
CA2505003A1 (en) 2004-05-27
NZ540384A (en) 2008-06-30
AU2003226361A1 (en) 2004-06-03
EP1569903A4 (en) 2009-07-29
WO2004043336A2 (en) 2004-05-27
IL168444A (en) 2010-12-30
CN1720226A (en) 2006-01-11
MXPA05004777A (en) 2005-07-22
US20060165649A1 (en) 2006-07-27
KR20050072790A (en) 2005-07-12
JP2006507324A (en) 2006-03-02
ZA200503653B (en) 2006-08-30
EP1569903A2 (en) 2005-09-07

Similar Documents

Publication Publication Date Title
EP2210606A3 (en) Compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
WO2005043971A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
MX358515B (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes.
WO2005046318A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
IL178591A (en) 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for the treatment and management of myelodysplastic syndromes
WO2005105088A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
NO20061859L (en) OROS Push Stick for controlled delivery of active agents
WO2004037207A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
WO2006017505A3 (en) Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
WO2004034962A3 (en) Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
WO2004043378A3 (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
WO2004043336A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
EP1666064A4 (en) Remedy for diseases associated with immunoglobulin gene translocation
WO2004037199A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2005110085A3 (en) Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
WO2005039497A3 (en) Methods and compositions comprising thalidomide for treatment of fibromyalgia
WO2004041190A3 (en) Composition for the treatment of macular degenration
ES2307896T3 (en) USE OF 4- (2-FLUOROPHENYL) -6-METHYL-2- (1-PIPERAZINYL) TIENO (2,3-D) -PIRIMIDINE FOR THE TREATMENT OF URINARY INCONTINENCE.
WO2005046594A3 (en) Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
WO2004041181A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
WO2004029025A3 (en) Methods and compositions for the treatment of autoimmune disorders using clofarabine
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
MXPA05009435A (en) Selective cytokine inhibitory drugs for treating disorders of the central nervous system.
WO2005094218A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2505003

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/004777

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 168444

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005/03653

Country of ref document: ZA

Ref document number: 1020057008025

Country of ref document: KR

Ref document number: 2004551394

Country of ref document: JP

Ref document number: 200503653

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003226361

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 540384

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003811178

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038257637

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057008025

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003811178

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0316002

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2006165649

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10534324

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10534324

Country of ref document: US